Crescent Biopharma offers an asymmetric risk/reward setup and an oversold technical pullback that the engine flags as a buying opportunity, but notable insider selling, a below-floor risk score, and a history of earnings misses keep the setup speculative and risk-heavy.
Thesis pillars
- Asymmetric Upside Reward Setup→Stable
- Oversold Pullback Opportunity↓Deteriorating
- Notable Insider Selling Signal→Stable
- +1 more pillar — see the Why tab for full reasoning
Pillars as of Jul 5, 2026, based on the 10-K filed Feb 26, 2026
Crescent Biopharma, Inc. (CBIO) Stock Analysis
Range Bound setup
Healthcare · Biotechnology
Sell if holding. Engine safety override at $13.50: Risk below floor (2.3 < 2.5) triggers a hard block regardless of the otherwise-positive setup — overall score 5.2/10 and A.R:R 7.0:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 20%; Below long-term trend.
Crescent Biopharma is a clinical-stage biotechnology company developing CR-001, a bispecific antibody designed to replicate the targeting, binding, cooperativity and pharmacokinetics of ivonescimab, alongside two antibody-drug conjugate programs, CR-002 and CR-003. The company... Read more
Sell if holding. Engine safety override at $13.50: Risk below floor (2.3 < 2.5) triggers a hard block regardless of the otherwise-positive setup — overall score 5.2/10 and A.R:R 7.0:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 20%; Below long-term trend. Chart setup: RSI 45 mid-range, Bollinger mid-band. Score 5.2/10, moderate confidence.
Passes 7/8 gates (favorable risk/reward ratio, clean insider activity, no SEC red flags, news events none recent, earnings proximity no date, semi cycle peak clear, materials cycle peak clear). Fails on weak momentum. Suitability: speculative.
Recent developments
updated 2026-10-29Recent Developments — Crescent Biopharma, Inc.
Latest news
- NEWS 5/2 Stocks On Watch AUPH AXTI BCRX CBIO CCCR CGNT CIDM CMRE CYCC KITE KERX KTOS RGLS Kidderminster Harriers (RLTne2YcaV) — Mshale neutral
- NEWS Crescent Biopharma Announces Grants of Inducement Awards - www.marketscreener.com — www.marketscreener.com neutral
- NEWS Stifel reiterates Buy on Crescent Biopharma stock, $28 target - Investing.com — Investing.com positive
- NEWS Crescent Biopharma stock rating upgraded to buy at H.C. Wainwright - Investing.com — Investing.com positive
- NEWS Stifel Maintains Crescent Biopharma(CBIO.US) With Buy Rating, Maintains Target Price $28 - Moomoo — Moomoo positive
Generated 2026-10-29T12:43:33Z.
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- HIGHpipelineCR-001, CR-002 and CR-00310-K Item 1A: 'We are substantially dependent on the success of our lead program, CR-001, as well as our ADC programs, CR-002 and CR-003, and our development programs may not be successful.'
- MEDIUMSuppliersingle-source unaffiliated third-party companies (drug delivery devices)10-K Item 1A: 'In addition, some drug delivery devices are provided by single-source unaffiliated third-party companies. We may be dependent on the sustained cooperation and effort of those third-party companies both to supply the devices'
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Editorial policy
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. People who build TrendMatrix, or entities they control, may hold positions, long or short, in securities it covers, and may trade them at any time. Positions are not disclosed individually. Verdicts are generated by an automated model applied by the same rules to every covered stock, and are not adjusted for any position held by the people who build TrendMatrix. We do not accept payment from issuers for coverage.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
3 floor-breakers
Volatile — 7.3% daily ATR makes tight stops impractical. Position-size conservatively.static
Technicals below the gate floor. Component breakdown shows what dragged the score down.static
No near-term catalyst priced in. Thesis progression will come from fundamentals grinding, not event reaction.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Engine safety override at $13.50: Risk below floor (2.3 < 2.5) triggers a hard block regardless of the otherwise-positive setup — overall score 5.2/10 and A.R:R 7.0:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 20%; Below long-term trend. Chart setup: RSI 45 mid-range, Bollinger mid-band. Prior stop was $12.56. Score 5.2/10, moderate confidence.
Analyst target: $27.41 (+103.0% upside). Prior stop was $12.56. Stop-loss: $12.56.
Concentration risk — Pipeline: CR-001, CR-002 and CR-003; Risk below floor (2.3 < 2.5).
Crescent Biopharma, Inc. trades at a P/E of N/A (forward -5.1). TrendMatrix value score: 5.4/10. Verdict: Sell.
14 analysts cover CBIO with a consensus score of 4.2/5. Average price target: $32.
What does Crescent Biopharma, Inc. do?Crescent Biopharma is a clinical-stage biotechnology company developing CR-001, a bispecific antibody designed to...
Crescent Biopharma is a clinical-stage biotechnology company developing CR-001, a bispecific antibody designed to replicate the targeting, binding, cooperativity and pharmacokinetics of ivonescimab, alongside two antibody-drug conjugate programs, CR-002 and CR-003. The company initiated the global Phase 1/2 ASCEND trial of CR-001 in the first quarter of 2026 across up to eight solid tumor types, has never generated revenue from product sales, and reported a net loss of $153.9 million for the year ended December 31, 2025. Crescent licenses core intellectual property underlying CR-001 from Parag